Illumina stock falls 2.71% and underperforms competitors

6 articles · Updated · MarketWatch · May 7

Shares closed at $138.71 on Thursday as the S&P 500 fell 0.38% and the Dow Jones Industrial Average dropped 0.63% in a broadly weak market.
Illumina lagged peers including Labcorp, up 0.43%, and Quest Diagnostics, up 0.90%, while Charles River Laboratories slipped 0.03%.
The stock finished 10.81% below its 52-week high of $155.53 reached on 22 January, and trading volume of 1.2 million was below its 50-day average.

With strong Q1 results and raised guidance, what explains the sudden, dramatic plunge in Illumina's stock price?

After the costly Grail failure, can new leadership navigate rising competition and justify Illumina's premium valuation?

Can Illumina's pivot to software protect its dominance as competitors launch sequencers for a fraction of the cost?